Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The Orcharrd Study (OMB110928)

Gustaaf W van Imhoff, MD PhD, Andrew McMillan, Matthew J. Matasar, MD MS, John Radford, MD FRCP, Kirit M Ardeshna, MD FRCPath, Kazimierz Kuliczkowski, WonSeog Kim, Xiaonan Hong, Jette Soenderskov Goerloev, Andrew Davies, María Dolores Caballero Barrigón, Michinori Ogura, MD PhD, Michael Fennessy, PhD, Qiming Liao, PhD, Bronno van der Holt, PhD, Steen Lisby, Thomas S. Lin, MD PhD, Anton Hagenbeek, MD PhD

Blood (2014) 124 (21): 630.

https://doi.org/10.1182/blood.V124.21.630.630

Published: 2014

Journal Articles

Survival Among Lymphoma Patients Over the Past Three Decades: A Single Institution Based Retrospective Review From 1976 to 2006.

Monika Joshi, MD, Hassan S Sheikh, M.D., Fabian Camacho, MS, Lisa A Hand, BS, CTR, Michael G. Bayerl, MD, Witold B Rybka, MD

Blood (2009) 114 (22): 4527.

https://doi.org/10.1182/blood.V114.22.4527.4527

Published: 2009

Journal Articles

Non-Hodgkin’s (NHL) Lymphoma Patients(pts) in the VA Population: Clinical Characteristics and Survival Predictors.

Michelle Cholankeril, MD, Donald Hoover, PhD, Shanti Srinivas, MD, Victor T. Chang, MD, Manzurul Sikder, MD, Melanie Gonzalez, BS, Basil Kasimis, MD

Blood (2007) 110 (11): 4435.

https://doi.org/10.1182/blood.V110.11.4435.4435

Published: 2007

Journal Articles

Myeloablative Allogeneic Stem Cell Transplantation for Relapsed Composite Low and Intermediate Grade Lymphoma Is Not Superior to Autologous Stem Cell Transplantation - Reduced Relapse Risk Is Offset by Higher Treatment Related Mortality.

Khaled M. Ramadan, Joseph M. Connors, Abdulwahab J. Al-Tourah, Randy D. Gascoyne, Kevin Song, Michael J. Barnett, Stephen H. Nantel, Thomas J. Nevill, John D. Shepherd, Heather J. Sutherland, Julye Lavoie, Donna L. Forrest, Donna E. Hogge, Nicholas J. Voss, Clayton A. Smith, Cynthia L. Toze

Blood (2006) 108 (11): 3039.

https://doi.org/10.1182/blood.V108.11.3039.3039

Published: 2006

Journal Articles

Allogeneic Hematopoietic Cell Transplantation (HCT) after Nonmyeloablative Conditioning for Relapsed or Refractory Follicular Lymphoma.

Michael B. Maris, MD, Brenda M. Sandmaier, MD, Barry Storer, PhD, Edward Agura, MD, James Wade, MD, Richard T. Maziarz, MD, Stephen Forman, MD, Judy Shizuru, MD, PhD, Thomas Chauncey, MD, PhD, Christoph Kahl, MD, Amelia A. Langston, MD, Dietger Niederwieser, MD, Rainer Storb, MD, David G. Maloney, MD

Blood (2005) 106 (11): 1130.

https://doi.org/10.1182/blood.V106.11.1130.1130

Published: 2005

Journal Articles

Phase 2 trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with poor-prognosis, intermediate-grade non-Hodgkin lymphoma: an Eastern Cooperative Oncology Group trial (E3493)

Joseph A. Sparano, Edie Weller, Tipu Nazeer, Thomas Habermann, Ann E. Traynor, Jane Manalo, Peter Cassileth

Blood (2002) 100 (5): 1634–1640.

https://doi.org/10.1182/blood.V100.5.1634.h81702001634_1634_1640

Published: 2002

Journal Articles

Clinical, biologic, and histologic features of late relapses in diffuse large cell lymphoma

F Cabanillas, WS Velasquez, FB Hagemeister, P McLaughlin, JR Redman

Blood (1992) 79 (4): 1024–1028.

https://doi.org/10.1182/blood.V79.4.1024.1024

Published: 1992

NARROW

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The Orcharrd Study (OMB110928)

Survival Among Lymphoma Patients Over the Past Three Decades: A Single Institution Based Retrospective Review From 1976 to 2006.

Non-Hodgkin’s (NHL) Lymphoma Patients(pts) in the VA Population: Clinical Characteristics and Survival Predictors.

Myeloablative Allogeneic Stem Cell Transplantation for Relapsed Composite Low and Intermediate Grade Lymphoma Is Not Superior to Autologous Stem Cell Transplantation - Reduced Relapse Risk Is Offset by Higher Treatment Related Mortality.

Allogeneic Hematopoietic Cell Transplantation (HCT) after Nonmyeloablative Conditioning for Relapsed or Refractory Follicular Lymphoma.

Phase 2 trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with poor-prognosis, intermediate-grade non-Hodgkin lymphoma: an Eastern Cooperative Oncology Group trial (E3493)

Clinical, biologic, and histologic features of late relapses in diffuse large cell lymphoma

Email alerts

ASH Publications

American Society of Hematology

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The Orcharrd Study (OMB110928)

Survival Among Lymphoma Patients Over the Past Three Decades: A Single Institution Based Retrospective Review From 1976 to 2006.

Non-Hodgkin’s (NHL) Lymphoma Patients(pts) in the VA Population: Clinical Characteristics and Survival Predictors.

Myeloablative Allogeneic Stem Cell Transplantation for Relapsed Composite Low and Intermediate Grade Lymphoma Is Not Superior to Autologous Stem Cell Transplantation - Reduced Relapse Risk Is Offset by Higher Treatment Related Mortality.

Allogeneic Hematopoietic Cell Transplantation (HCT) after Nonmyeloablative Conditioning for Relapsed or Refractory Follicular Lymphoma.

Phase 2 trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with poor-prognosis, intermediate-grade non-Hodgkin lymphoma: an Eastern Cooperative Oncology Group trial (E3493)

Clinical, biologic, and histologic features of late relapses in diffuse large cell lymphoma

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only